Screening Substances for Induced Pluripotent Stem Cell Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for drug screening for intractable diseases like fibrodysplasia ossificans progressiva, mitochondrial diseases, and lysosomal diseases are time-consuming and unreliable, as they do not effectively utilize cells derived from patients, making it difficult to evaluate medicinal effects and identify effective drug candidates.
Innovation Solution
A method is developed to screen substances that promote the induction of induced pluripotent stem cells from cells of patients with these diseases by using specific inhibitors like LDN193189 for ALK2 and sodium butyrate, allowing for the efficient generation of iPS cells even when conventional reprogramming methods fail.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional reprogramming methods are used to generate iPS cells from patient cells with intractable diseases, then the process is simple, but the induction efficiency is extremely low or impossible
Solution Approach 1:
The patent changes the chemical parameters of the culture medium by adding specific substances (ALK2 inhibitor LDN193189 at 3 μM, sodium butyrate at 5 mM, or vitamin C at 50 μM) to the reprogramming medium. This parameter change enables efficient iPS cell induction from patient cells with intractable diseases that otherwise would not respond to conventional reprogramming methods
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that mediate between the reprogramming factors and the patient cells. These compounds (ALK2 inhibitor, sodium butyrate, or vitamin C) act as chemical mediators that overcome the cellular barriers preventing iPS cell induction in disease-specific cells
2Reliability
If drug screening is performed using conventional cell lines or transgenic mice, then the screening process is straightforward, but the results do not reliably predict medicinal effects in human patients
Solution Approach 1:
The patent creates accurate biological copies of human patient cells (iPS cells) that retain the original disease characteristics. These copied cells serve as in vitro models that reliably predict drug efficacy in human patients, replacing the need for transgenic mice while maintaining physiological relevance
Solution Approach 2:
The patent enables patient-specific cells to serve their own therapeutic evaluation purpose. By generating iPS cells from each patient's own cells, the system allows each patient's cells to self-evaluate potential drug responses, providing personalized medicine insights without requiring external model systems
3Measurement precision
If iPS cells are attempted to be generated from cells of patients with intractable diseases, then patient-specific disease modeling is achieved, but the induction process fails or is extremely inefficient
Solution Approach 1:
The patent modifies the cultural parameters by adding specific chemicals to the medium, which changes the cellular environment to one that supports reprogramming of previously refractory patient cells. This parameter adjustment enables both efficient generation and accurate disease phenotype reproduction
Data Source
AI summary
The object of the present invention is to provide a method for screening a substance capable of promoting induction of induced pluripotent stem cells from cells derived from an individual affected by a disease for which it is impossible to produce induced pluripotent stem cells simply by introducing reprogramming genes. The present invention provides a method for screening a substance, which comprises culturing cells derived from an individual affected by a disease for which it is impossible to produce induced pluripotent stem cells simply by introducing reprogramming genes, the cells being transfected with reprogramming genes, in the presence of test substances, and selecting a test substance capable of promoting induction of induced pluripotent stem cells from the cells.